The US Food and Drug Administration has announced the approval of a new combination treatment for hepatitis C virus.
Hepatitis C does not contribute to mental impairment in patients who are coinfected with HIV when there is an absence of substantial liver damage, according to a study published online in the journal Neurology.
Recent updates of guidelines for the treatment of Hepatitis C recommends priority to the sickest patients with advanced fibrosis, compensated cirrhosis or those in need of a liver transplant.
A committee for the European Medicines Agency has recommended approval for a hepatitis C drug combination, a key step to winning European marketing authorization for the drug maker AbbVie. The recommendation for marketing authorization is for AbbVie’s investigational drug named Exviera (dasabuvir) and Viekirax (ombitasvir, paritaprevir and ritonavir) for the treatment of chronic hepatitis C virus infection in combination with other medicine.
The US Food and Drug Administration recently rejected a bid by Bristol-Myers Squibb to win regulatory approval for its hepatitis C drug daclatasvir, pending further information requested in a Complete Response Letter issued by the agency.
Hepatitis C virus, fibrosis, and cirrhosis patients with sustained virological response can have survival rates comparable to the general population, according to research published in JAMA.